



US009090653B2

(12) **United States Patent**
Aciro et al.

(10) **Patent No.:** **US 9,090,653 B2**
(45) **Date of Patent:** ***Jul. 28, 2015**

(54) **MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES**
(71) Applicants: **Gilead Sciences, Inc.**, Foster City, CA (US); **Selcia Ltd.**, Ongar, Essex (GB)
(72) Inventors: **Caroline Aciro**, Bottisham (GB); **Victoria Alexandra Steadman**, Stansted (GB); **Simon Neil Pettit**, Colchester (GB); **Karine G. Poulennec**, Chelmsford (GB); **Linos Lazarides**, London (GB); **David Kenneth Dean**, Ware (GB); **Neil Andrew Dunbar**, Chelmsford (GB); **Adrian John Highton**, Chelmsford (GB); **Andrew John Keats**, Chelmsford (GB); **Dustin Scott Siegel**, Foster City, CA (US); **Kapil Kumar Karki**, Foster City, CA (US); **Adam James Schrier**, Redwood City, CA (US); **Petr Jansa**, San Mateo, CA (US); **Richard Mackman**, Millbrae, CA (US)

(73) Assignees: **Gilead Sciences, Inc.**, Foster City, CA (US); **Selcia Ltd.**, Ongar (GB)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/913,184**

(22) Filed: **Jun. 7, 2013**

(65) **Prior Publication Data**

US 2013/0344029 A1 Dec. 26, 2013

Related U.S. Application Data

(60) Provisional application No. 61/657,553, filed on Jun. 8, 2012.

(51) **Int. Cl.**

A61K 38/21 (2006.01)
C07K 5/02 (2006.01)
C07D 487/08 (2006.01)
C07D 498/08 (2006.01)
C07D 498/18 (2006.01)
C07K 5/062 (2006.01)
A61K 38/12 (2006.01)
A61K 39/29 (2006.01)
A61K 45/06 (2006.01)
C07D 471/18 (2006.01)
C07D 498/22 (2006.01)
A61K 38/55 (2006.01)
A61K 31/403 (2006.01)
A61K 31/497 (2006.01)
A61K 31/504 (2006.01)
A61K 31/7056 (2006.01)
A61K 31/7072 (2006.01)
C07K 5/078 (2006.01)
C07K 5/065 (2006.01)
A61K 38/15 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 5/02** (2013.01); **A61K 31/403** (2013.01); **A61K 31/497** (2013.01); **A61K**

31/504 (2013.01); **A61K 31/7056** (2013.01); **A61K 31/7072** (2013.01); **A61K 38/12** (2013.01); **A61K 38/21** (2013.01); **A61K 38/55** (2013.01); **A61K 39/29** (2013.01); **A61K 45/06** (2013.01); **C07D 471/18** (2013.01); **C07D 487/08** (2013.01); **C07D 498/08** (2013.01); **C07D 498/18** (2013.01); **C07D 498/22** (2013.01); **C07K 5/0606** (2013.01); **C07K 5/06034** (2013.01); **C07K 5/06052** (2013.01); **C07K 5/06078** (2013.01); **C07K 5/06139** (2013.01); **A61K 38/15** (2013.01)

(58) **Field of Classification Search**
CPC **A61K 38/12**; **A61K 38/15**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,513,184 B2 * 8/2013 Appelby et al. 514/1.1

FOREIGN PATENT DOCUMENTS

WO WO 2006/138507 A1 12/2006
WO WO 2012/078915 A1 6/2012

OTHER PUBLICATIONS

International Search Report from PCT/US2013/044809 issued Sep. 16, 2013 by the European Patent Office.
U.S. Appl. No. 13/942,501, filed Jul. 15, 2013, Appelby et al.
U.S. Appl. No. 13/913,259 Non-Final Rejection mailed Aug. 29, 2014.
U.S. Appl. No. 13/913,288 Non-Final Rejection mailed Aug. 28, 2014.

* cited by examiner


Primary Examiner — Marcela M Cordero Garcia

Assistant Examiner — Kaipeen Yang

(74) *Attorney, Agent, or Firm* — Francis O. Ginah

(57) **ABSTRACT**

Provided are compounds of Formula I:



Formula I

and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

19 Claims, No Drawings